Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Jan. 31, 2014
Jan. 31, 2013
Jan. 31, 2014
Jan. 31, 2013
Revenues:        
Clinical laboratory services $ 13,848 $ 13,320 $ 28,707 $ 28,497
Product revenues 8,054 7,876 15,717 16,309
Royalty and license fee income 1,026 1,014 2,637 3,033
Total revenues 22,928 22,210 47,061 47,839
Operating expenses:        
Cost of clinical laboratory services 9,292 9,425 19,001 19,135
Cost of product revenues 3,865 4,143 7,712 8,327
Research and development 832 968 1,649 1,979
Selling, general, and administrative 10,084 10,892 20,612 22,308
Provision for uncollectible accounts receivable 912 1,335 1,784 2,929
Legal 1,496 1,441 2,877 3,142
Total operating expenses 26,481 28,204 53,635 57,820
Operating loss (3,553) (5,994) (6,574) (9,981)
Other income (expense):        
Interest (52) (7) (114) (15)
Other 15 43 76 56
Foreign currency gain 20 104 317 333
Loss before income taxes (3,570) (5,854) (6,295) (9,607)
(Provision) benefit for income taxes 4 180 (58) 242
Net loss $ (3,566) $ (5,674) $ (6,353) $ (9,365)
Net loss per common share:        
Basic and diluted (in Dollars per share) $ (0.09) $ (0.14) $ (0.15) $ (0.24)
Weighted average common shares outstanding:        
Basic and diluted (in Shares) 41,887 39,312 41,472 39,295